Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Inovio CEO Interview: PD1/PDL1 Inhibitors, Immunotherapy And Why Investors Should Be Excited About 2014
Inovio CEO Interview: PD1/PDL1 Inhibitors, Immunotherapy And Why Investors Should Be Excited About 2014
Inovio CEO Interview: PD1/PDL1 Inhibitors, Immunotherapy And Why Investors Should Be Excited About 2014
Submitted by
admin
on December 20, 2013 - 11:49am
Source:
Seeking Alpha
News Tags:
Inovio
Pharma CEOs
PDL-1
immunotherapy
Joseph Kim
Bristol-Myers Squibb
Roche
Dendreon
GSK
ImmunoCellular Therapeutics
Merck
Northwest Biotherapeutics
Headline:
Inovio CEO Interview: PD1/PDL1 Inhibitors, Immunotherapy And Why Investors Should Be Excited About 2014
Do Not Allow Advertisers to Use My Personal information
